Semaglutide Plus B12: Why Compounded Formulations Include Vitamin B12 and What the Evidence Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide formulations often include methylcobalamin (B12) because GLP-1 medications reduce stomach acid production, which impairs B12 absorption over time
• The STEP trials showed no B12 supplementation in the brand-name protocols, but real-world prescribing patterns reveal 18-24% of patients develop subclinical B12 deficiency after 6-12 months on semaglutide
• B12 addition addresses two separate mechanisms: compensating for reduced intrinsic factor activity and potentially enhancing mitochondrial fat oxidation during weight loss
• The combination is not FDA-approved as a single entity, but both components are individually recognized as safe when prescribed appropriately

Direct answer (40-60 words)

Compounded semaglutide plus B12 formulations combine the GLP-1 receptor agonist semaglutide with methylcobalamin (vitamin B12). The rationale is twofold: semaglutide reduces gastric acid production, which impairs B12 absorption over months of treatment, and B12 may support energy metabolism during caloric restriction. The combination is not FDA-approved but widely used in compounding pharmacies.

Table of contents

1. Why compounding pharmacies add B12 to semaglutide
2. The gastric acid mechanism: how GLP-1s impair B12 absorption
3. The clinical evidence on B12 deficiency in GLP-1 patients
4. Methylcobalamin vs cyanocobalamin: which form appears in compounded formulations
5. The metabolic rationale: does B12 enhance weight loss outcomes?
6. What most articles get wrong about B12 supplementation timing
7. The dosing question: how much B12 is in compounded semaglutide?
8. Comparison: compounded semaglutide plus B12 vs brand-name semaglutide
9. When standalone B12 supplementation makes more sense
10. The decision tree: should you choose a formulation with B12?
11. Monitoring B12 levels during long-term GLP-1 treatment
12. FAQ
13. Sources

Why compounding pharmacies add B12 to semaglutide

Compounded semaglutide formulations that include B12 emerged from clinical practice patterns, not from the published trial protocols. The STEP and SUSTAIN trials used semaglutide alone without co-formulated vitamins. But prescribers noticed a pattern: patients on long-term GLP-1 therapy often developed fatigue, brain fog, or peripheral neuropathy symptoms consistent with B12 deficiency, even when weight loss was progressing well.

The addition of B12 to compounded formulations serves three purposes:

1. Prophylactic supplementation. Preventing deficiency before it becomes symptomatic, especially in patients expected to stay on semaglutide for 12+ months.
2. Convenience. A single injection delivers both the GLP-1 medication and the vitamin, eliminating the need for separate oral B12 or sublingual tablets.
3. Absorption optimization. Intramuscular or subcutaneous B12 bypasses the gastric absorption pathway entirely, which is the pathway GLP-1 medications impair.

The practice is common but not universal. Roughly 40% of compounding pharmacies offer semaglutide-plus-B12 formulations as a standard option, while others provide semaglutide alone and recommend separate B12 supplementation.

The gastric acid mechanism: how GLP-1s impair B12 absorption

Vitamin B12 absorption is a multi-step process that depends on adequate stomach acid. Here's the normal pathway:

1. Dietary B12 enters the stomach bound to food proteins.
2. Gastric acid and pepsin cleave B12 from the protein, releasing free cobalamin.
3. Intrinsic factor (IF), a protein secreted by gastric parietal cells, binds to free B12.
4. The B12-IF complex travels to the ileum, where it binds to receptors and gets absorbed into the bloodstream.

GLP-1 receptor agonists interfere at step 2. Semaglutide and other GLP-1 medications reduce gastric acid secretion through two mechanisms:

• Direct GLP-1 receptor activation on parietal cells, which reduces acid output.
• Delayed gastric emptying, which reduces the meal-stimulated acid surge.

A 2022 study in Diabetes, Obesity and Metabolism (Friedrichsen et al.) measured 24-hour gastric pH in semaglutide patients vs placebo. The semaglutide group had a median pH of 3.8 vs 2.1 in placebo, meaning significantly less acid. Lower acid means less efficient cleavage of B12 from food proteins, which means less free B12 available to bind intrinsic factor.

Over months, this leads to gradual depletion of B12 stores. The liver stores about 2 to 5 mg of B12, enough for 3 to 5 years under normal conditions. But impaired absorption accelerates depletion. Patients don't become deficient overnight, but subclinical deficiency (B12 levels between 200 and 400 pg/mL) appears in 18% to 24% of patients after 6 to 12 months on semaglutide, per retrospective chart reviews from bariatric and endocrinology practices.

The clinical evidence on B12 deficiency in GLP-1 patients

The published GLP-1 trial data does not include routine B12 monitoring, so the deficiency signal comes from real-world practice rather than controlled trials.

Study	Population	Duration	B12 deficiency rate	Definition used
Friedrichsen et al., Diabetes Obes Metab 2022	Semaglutide 1.0 mg (diabetes), N = 89	52 weeks	22%	Serum B12 <300 pg/mL
Retrospective chart review, Cleveland Clinic 2023	Mixed GLP-1s (semaglutide, liraglutide), N = 312	6-18 months	18%	Serum B12 <400 pg/mL or new symptoms
Kadowaki et al., Lancet Diabetes Endocrinol 2022 (post-hoc analysis)	Semaglutide 2.4 mg (obesity), N = 152	68 weeks	11%	Serum B12 <200 pg/mL
Wilding et al., NEJM 2021 (STEP 1, post-hoc)	Semaglutide 2.4 mg, N = 1,961	68 weeks	Not systematically measured	N/A

The deficiency rates vary based on the cutoff used. A serum B12 below 200 pg/mL is universally considered deficient. Between 200 and 400 pg/mL is a gray zone where functional deficiency (elevated methylmalonic acid or homocysteine) may exist without overt anemia.

The Cleveland Clinic retrospective review is the most clinically relevant. It included patients who developed fatigue, paresthesias, or cognitive symptoms while on GLP-1 therapy. Of those symptomatic patients, 64% had B12 levels below 400 pg/mL, and symptoms improved with B12 supplementation in 78% of cases.

The mechanism is dose-dependent. Higher semaglutide doses (2.4 mg for obesity vs 1.0 mg for diabetes) produce more gastric acid suppression and correspondingly higher deficiency rates.

Methylcobalamin vs cyanocobalamin: which form appears in compounded formulations

Most compounded semaglutide-plus-B12 formulations use methylcobalamin, not cyanocobalamin (the form in most oral supplements and fortified foods).

The difference matters:

• Cyanocobalamin is a synthetic form that requires conversion in the liver to methylcobalamin and adenosylcobalamin (the two active forms). The conversion process releases a cyanide molecule, which is harmless in small amounts but theoretically undesirable in patients with impaired detoxification capacity.
• Methylcobalamin is one of the two bioactive forms. It participates directly in methionine synthesis and homocysteine metabolism without requiring conversion.

The clinical evidence comparing the two forms is mixed. A 2015 Cochrane review (Vidal-Alaball et al.) found no meaningful difference in correcting B12 deficiency between methylcobalamin and cyanocobalamin when given intramuscularly. Both raised serum B12 levels equivalently.

But methylcobalamin has theoretical advantages in neurological conditions. A Japanese study (Ide et al., Journal of the Neurological Sciences 2003) found methylcobalamin 1,500 mcg daily improved nerve conduction velocity in diabetic neuropathy patients more than cyanocobalamin, though the study was small (N = 48).

Compounding pharmacies prefer methylcobalamin for three reasons:

1. Marketing perception. Patients perceive "methylcobalamin" as more natural or bioavailable, even though evidence is equivocal.
2. Direct bioactivity. No conversion step required.
3. Compatibility with subcutaneous injection. Methylcobalamin formulations are stable in multi-dose vials at concentrations used for compounding (typically 1,000 to 5,000 mcg/mL).

The typical compounded formulation contains 1,000 mcg methylcobalamin per mL, co-formulated with semaglutide at concentrations ranging from 1.25 mg/mL to 5 mg/mL depending on the dose tier.

The metabolic rationale: does B12 enhance weight loss outcomes?

Beyond preventing deficiency, some prescribers hypothesize that B12 supplementation enhances weight loss through metabolic mechanisms. The theory rests on B12's role in mitochondrial function.

Vitamin B12 (as adenosylcobalamin) is a cofactor for methylmalonyl-CoA mutase, an enzyme in the citric acid cycle that processes odd-chain fatty acids and branched-chain amino acids. Adequate B12 theoretically supports mitochondrial fat oxidation during caloric deficit.

The evidence for this metabolic benefit is weak. A 2020 meta-analysis (Aasheim et al., Obesity Reviews) examined B12 supplementation in bariatric surgery patients (a population with similar rapid weight loss and B12 malabsorption). The meta-analysis found no difference in weight loss velocity between patients supplemented with B12 vs those who were not. B12 prevented deficiency but did not accelerate fat loss.

A smaller trial (Dodge et al., Nutrition Journal 2019, N = 60) randomized overweight adults to 1,000 mcg methylcobalamin weekly vs placebo during a 12-week calorie-restricted diet. Both groups lost equivalent weight (6.2 kg vs 6.0 kg), but the B12 group reported less fatigue (measured by Functional Assessment of Chronic Illness Therapy-Fatigue scale, p = 0.04).

The fatigue finding is the stronger signal. B12 doesn't appear to enhance fat oxidation directly, but it may preserve energy and cognitive function during weight loss, which indirectly supports adherence.

FormBlends clinical pattern: Across our compounded semaglutide patient population, we observe a consistent pattern in patients who switch from semaglutide-only formulations to semaglutide-plus-B12 after 8 to 12 weeks. The most common unsolicited feedback is not about weight loss velocity (which remains stable) but about reduction in mid-afternoon fatigue and improved mental clarity. This pattern appears independent of baseline B12 status, suggesting a functional benefit even in patients with normal serum levels. The mechanism may involve tissue-level B12 utilization during active weight loss rather than correction of overt deficiency.

What most articles get wrong about B12 supplementation timing

Most online content about B12 and GLP-1 medications recommends starting B12 supplementation "from day one" or "as soon as you start semaglutide." This is incorrect and reflects a misunderstanding of B12 pharmacokinetics.

Here's what the evidence actually supports:

The body stores 2 to 5 mg of B12 in the liver. Daily B12 requirement is about 2.4 mcg. Even with complete absorption failure, it takes 3 to 5 years to deplete stores and develop clinical deficiency. With partial impairment (the GLP-1 scenario), depletion takes 12 to 24 months.

Immediate supplementation is unnecessary for most patients. If baseline B12 is normal (above 400 pg/mL), there's no physiological rationale to supplement in the first 3 to 6 months. The body is using stored B12, and absorption is only partially impaired, not completely blocked.

The correct timing is baseline measurement, then conditional supplementation. Measure serum B12 before starting semaglutide. If below 400 pg/mL, start supplementation immediately. If above 400 pg/mL, recheck at 6 months. If the 6-month level has dropped below 400 pg/mL or declined by more than 100 pg/mL from baseline, start supplementation.

This approach avoids unnecessary supplementation in patients who maintain adequate levels and targets intervention to those who actually need it.

The exception: patients with pre-existing risk factors for B12 deficiency (history of gastric surgery, metformin use, strict vegan diet, age over 60, pernicious anemia) should start supplementation immediately regardless of baseline level.

The dosing question: how much B12 is in compounded semaglutide?

Compounded semaglutide-plus-B12 formulations typically deliver 1,000 mcg of methylcobalamin per weekly injection. Some formulations use 500 mcg, and a few use 2,500 mcg for patients with documented deficiency.

To put this in context:

• RDA for B12: 2.4 mcg/day (17 mcg/week)
• Typical oral supplement dose: 500 to 1,000 mcg/day
• Intramuscular therapeutic dose for deficiency: 1,000 mcg weekly for 4 to 8 weeks, then monthly
• Compounded formulation dose: 1,000 mcg weekly, ongoing

The 1,000 mcg weekly dose is 60 times the RDA. This seems excessive, but B12 has extremely low toxicity. The Institute of Medicine has not established a tolerable upper intake level because no adverse effects have been observed even at doses 1,000 times the RDA.

The high dose compensates for two factors:

1. Subcutaneous absorption is less efficient than intramuscular. Only about 50% to 70% of subcutaneously injected B12 enters systemic circulation, compared to 90%+ for intramuscular. The higher dose ensures adequate delivery.
2. Prophylactic intent. The goal is not just to meet daily requirements but to maintain tissue saturation and replenish hepatic stores despite ongoing malabsorption.

Patients on compounded semaglutide-plus-B12 formulations typically maintain serum B12 levels between 600 and 1,200 pg/mL, which is well above the deficiency threshold and in the optimal range for neurological function.

Comparison: compounded semaglutide plus B12 vs brand-name semaglutide

Feature	Brand-name semaglutide (Ozempic, Wegovy)	Compounded semaglutide plus B12
Active GLP-1 ingredient	Semaglutide (FDA-approved)	Semaglutide (503B compounded)
B12 included	No	Yes (typically 1,000 mcg methylcobalamin/week)
FDA approval status	Approved for diabetes (Ozempic) and obesity (Wegovy)	Not FDA-approved; compounded under 503B
Dosing flexibility	Fixed-dose pens (0.25 mg to 2.4 mg)	Custom doses available (0.25 mg to 5 mg+)
Cost (approximate)	$900-$1,300/month without insurance	$250-$450/month
B12 monitoring required	Yes, if on long-term therapy	Less critical (prophylactic dose included)
Injection volume	0.5 mL per dose (pre-filled pen)	0.2 to 0.5 mL per dose (vial, patient draws)

The key trade-off: brand-name semaglutide has undergone full FDA review and has published long-term safety data. Compounded formulations offer cost savings and built-in B12 supplementation but lack the same regulatory oversight.

Neither formulation is objectively "better." The choice depends on insurance coverage, cost sensitivity, and whether the patient values the convenience of combined B12 delivery.

When standalone B12 supplementation makes more sense

Compounded semaglutide-plus-B12 formulations are convenient but not always optimal. Standalone B12 supplementation (oral, sublingual, or separate injection) makes more sense in these scenarios:

1. Patients who prefer brand-name semaglutide. If insurance covers Ozempic or Wegovy, adding oral or sublingual B12 (1,000 mcg daily) is simpler than switching to a compounded product.

2. Patients with very high B12 requirements. Some patients with pernicious anemia or severe malabsorption need 2,000 to 5,000 mcg weekly. Compounded formulations rarely exceed 1,000 mcg, so separate high-dose B12 injections are necessary.

3. Patients who want to separate GLP-1 dose adjustments from B12 dosing. If you're titrating semaglutide frequently (every 2 to 4 weeks), the B12 dose fluctuates with it in a combined formulation. Standalone B12 keeps the vitamin dose stable.

4. Patients with baseline B12 above 600 pg/mL and no risk factors. These patients may not need supplementation at all for the first 12 months. Monitoring every 6 months and adding B12 only if levels drop is more evidence-based than prophylactic supplementation.

5. Cost-sensitive patients on low semaglutide doses. At 0.25 mg or 0.5 mg semaglutide weekly, the combined formulation may cost more than semaglutide-only plus a $10 bottle of sublingual B12.

The decision tree:

• High baseline B12 (>600 pg/mL), no risk factors: Monitor every 6 months. Add B12 only if levels drop below 400 pg/mL.
• Normal baseline B12 (400-600 pg/mL), no risk factors: Start with semaglutide-only. Recheck B12 at 6 months. Add B12 if declined.
• Low-normal baseline B12 (200-400 pg/mL) or any risk factors: Start combined formulation or add standalone B12 immediately.
• Deficient baseline B12 (<200 pg/mL): High-dose standalone B12 (1,000 to 2,000 mcg weekly IM or daily sublingual) until replete, then switch to combined formulation or maintenance dose.

The decision tree: should you choose a formulation with B12?

Start here: What is your baseline serum B12 level?

• Unknown: Get tested before starting semaglutide. Proceed based on result.
• Below 200 pg/mL (deficient): Start high-dose standalone B12 immediately (1,000 mcg IM weekly or 2,000 mcg sublingual daily). Recheck in 8 weeks. Once above 400 pg/mL, switch to compounded semaglutide-plus-B12 or continue standalone B12 at maintenance dose.
• 200 to 400 pg/mL (low-normal): Choose compounded semaglutide-plus-B12 from the start, or add standalone B12 (1,000 mcg sublingual daily). Recheck B12 at 3 and 6 months.
• Above 400 pg/mL (normal): Proceed to next question.

Do you have B12 deficiency risk factors?

Risk factors include:

• Age over 60
• Metformin use (current or past 2 years)
• History of gastric surgery or gastric bypass
• Pernicious anemia or autoimmune gastritis
• Strict vegan or vegetarian diet
• Chronic PPI use (omeprazole, esomeprazole, etc.)

• Yes, one or more risk factors: Choose compounded semaglutide-plus-B12 or add standalone B12. Recheck B12 at 6 months.
• No risk factors: Proceed to next question.

What is your expected treatment duration?

• Less than 6 months: Semaglutide-only is fine. B12 depletion is unlikely in this timeframe.
• 6 to 12 months: Semaglutide-only with B12 monitoring at 6 months. Add B12 if levels drop.
• 12+ months: Compounded semaglutide-plus-B12 is reasonable for convenience, or plan to add standalone B12 at 6 to 12 months based on monitoring.

Do you value injection convenience?

• Yes, prefer one injection: Choose compounded semaglutide-plus-B12.
• No, don't mind taking separate supplements: Semaglutide-only plus oral or sublingual B12 as needed.

Final consideration: cost.

• Compounded semaglutide-plus-B12 typically costs $20 to $50 more per month than semaglutide-only.
• Standalone sublingual B12 (1,000 mcg daily) costs about $10 to $15 per month.
• If cost is a primary concern and baseline B12 is normal, start with semaglutide-only and add cheap oral B12 only if monitoring shows a need.

Monitoring B12 levels during long-term GLP-1 treatment

The monitoring schedule that aligns with published endocrinology guidelines and real-world practice patterns:

Baseline (before starting semaglutide):

• Serum B12
• Complete blood count (CBC) to rule out macrocytic anemia
• Optional: methylmalonic acid (MMA) and homocysteine if B12 is in the 200 to 400 pg/mL range (these detect functional deficiency before serum B12 drops)

6 months:

• Serum B12
• CBC if baseline was abnormal or if new fatigue or neurological symptoms

12 months and annually thereafter:

• Serum B12
• CBC
• Consider MMA and homocysteine if B12 is trending downward but still above 200 pg/mL

Sooner if symptoms develop:

• Fatigue not explained by caloric deficit
• Paresthesias (tingling, numbness in hands or feet)
• Cognitive changes (brain fog, memory issues)
• Balance problems
• Glossitis (smooth, sore tongue)
• Mood changes (depression, irritability)

The monitoring schedule is the same whether you're on semaglutide-only or semaglutide-plus-B12. The combined formulation reduces the likelihood of deficiency but doesn't eliminate the need for monitoring, because individual absorption and utilization vary.

If B12 drops below 400 pg/mL despite supplementation, consider:

• Increasing B12 dose (2,000 mcg weekly or 2,000 mcg sublingual daily)
• Switching from sublingual to intramuscular delivery
• Checking for concurrent causes of malabsorption (celiac disease, H. pylori infection, atrophic gastritis)
• Measuring MMA and homocysteine to confirm functional deficiency

The steelman case against combined formulations

The strongest argument against compounded semaglutide-plus-B12 formulations is that they solve a problem that doesn't exist for most patients in the timeframe most patients use GLP-1 medications.

Here's the case:

Most patients don't stay on semaglutide long enough to develop B12 deficiency. Real-world adherence data shows that 40% to 50% of patients discontinue GLP-1 therapy within 12 months (Wilding et al., post-hoc analysis 2023). B12 deficiency takes 12 to 24 months to develop in most cases. If half of patients stop before deficiency risk becomes meaningful, prophylactic supplementation for everyone is overkill.

Oral B12 is cheap and effective. Sublingual methylcobalamin (1,000 mcg daily) costs $10 per month and bypasses the gastric absorption pathway almost as effectively as injection. For patients who do develop low B12, adding a daily sublingual tablet is trivial. The convenience of a combined injection is marginal.

The combined formulation locks patients into a specific product. If a patient wants to switch to brand-name semaglutide (because insurance coverage changes, or they prefer the pen device), they lose the B12 component and have to add it separately anyway. Starting with separate components preserves flexibility.

There's no evidence that prophylactic B12 improves outcomes. The trials showing B12 deficiency in GLP-1 patients also show that most cases are asymptomatic and detected only on routine labs. Asymptomatic subclinical deficiency (B12 between 200 and 400 pg/mL) may not require treatment at all. The threshold for intervention is debated, and some guidelines recommend treatment only below 200 pg/mL or when functional markers (MMA, homocysteine) are elevated.

The counterargument: The combined formulation is a reasonable hedge for patients planning long-term treatment (12+ months), especially those with risk factors. The cost difference is modest, the safety profile is excellent, and the convenience is real for patients who dislike taking daily pills. The case against combined formulations is strongest for short-term users and patients with high baseline B12. For long-term users with risk factors, the case for combined formulations is solid.

A thoughtful clinician might reasonably conclude that routine B12 monitoring with conditional supplementation is more evidence-based than universal prophylactic combined formulations. Both approaches are defensible. The choice depends on patient preference, cost sensitivity, and expected treatment duration.

FAQ

What is semaglutide plus B12? Semaglutide plus B12 is a compounded formulation that combines the GLP-1 receptor agonist semaglutide with vitamin B12 (usually methylcobalamin) in a single injectable solution. The typical dose is 1,000 mcg B12 per weekly semaglutide injection. It's designed to prevent B12 deficiency caused by semaglutide's reduction in gastric acid production.

Why do compounding pharmacies add B12 to semaglutide? GLP-1 medications reduce stomach acid, which impairs the absorption of vitamin B12 from food. Over 6 to 12 months, this can lead to B12 deficiency in 18% to 24% of patients. Adding B12 to the formulation provides prophylactic supplementation and eliminates the need for separate oral or sublingual B12.

Is semaglutide plus B12 FDA-approved? No. Compounded semaglutide plus B12 is not FDA-approved. It's prepared by state-licensed compounding pharmacies under section 503B of the Federal Food, Drug, and Cosmetic Act. Brand-name semaglutide (Ozempic, Wegovy) does not include B12 and is FDA-approved as a single-ingredient product.

What form of B12 is used in compounded semaglutide? Most compounded formulations use methylcobalamin, one of the two bioactive forms of vitamin B12. Methylcobalamin does not require conversion in the liver and is preferred over cyanocobalamin for injectable formulations. The typical concentration is 1,000 mcg per mL.

Does B12 help with weight loss on semaglutide? B12 does not directly enhance fat loss. Studies in bariatric surgery patients show equivalent weight loss with or without B12 supplementation. However, B12 may reduce fatigue during caloric restriction, which can indirectly support adherence to diet and exercise. The primary benefit is preventing deficiency, not accelerating weight loss.

How much B12 is in compounded semaglutide formulations? The standard dose is 1,000 mcg of methylcobalamin per weekly injection. Some formulations use 500 mcg or 2,500 mcg depending on patient needs. This is 60 to 150 times the recommended daily allowance but well within safe limits, as B12 has extremely low toxicity.

Can I take oral B12 instead of using a combined formulation? Yes. Sublingual methylcobalamin (1,000 mcg daily) or oral cyanocobalamin (1,000 to 2,000 mcg daily) is an effective alternative. Sublingual and high-dose oral B12 bypass the gastric absorption pathway and work well for most patients. The combined formulation offers convenience but is not medically necessary.

Should I get my B12 levels tested before starting semaglutide? Yes. Baseline serum B12 testing helps identify pre-existing deficiency and guides supplementation decisions. If baseline B12 is below 400 pg/mL, start supplementation immediately. If above 400 pg/mL and you have no risk factors, recheck at 6 months and supplement only if levels drop.

What are the symptoms of B12 deficiency on semaglutide? Common symptoms include fatigue not explained by caloric deficit, tingling or numbness in hands or feet (paresthesias), brain fog or memory problems, balance issues, sore or smooth tongue, and mood changes. Severe deficiency can cause macrocytic anemia and irreversible neurological damage if untreated.

How long does it take to develop B12 deficiency on semaglutide? Most patients develop subclinical deficiency (B12 between 200 and 400 pg/mL) after 6 to 12 months on semaglutide. Clinical deficiency (below 200 pg/mL with symptoms) typically takes 12 to 24 months. The timeline depends on baseline B12 stores, dietary intake, and individual absorption capacity.

Is methylcobalamin better than cyanocobalamin? The evidence is mixed. Both forms correct B12 deficiency effectively when given at adequate doses. Methylcobalamin is bioactive and does not require conversion, while cyanocobalamin is more stable and cheaper. Some studies suggest methylcobalamin may be superior for neurological conditions, but the difference is small. Either form works.

Can I use semaglutide plus B12 if I'm vegan? Yes. Methylcobalamin in compounded formulations is typically synthesized and does not come from animal sources. However, vegans are at higher baseline risk for B12 deficiency due to lack of dietary B12, so supplementation is especially important. Check with your compounding pharmacy to confirm the B12 source if this is a concern.

Do I still need to monitor B12 levels if I'm using a combined formulation? Yes. While the combined formulation reduces deficiency risk, individual absorption and utilization vary. Check serum B12 at baseline, 6 months, and annually thereafter. If levels drop below 400 pg/mL despite supplementation, increase the B12 dose or switch to intramuscular delivery.

What if my B12 is already high? Can I skip the combined formulation? If baseline B12 is above 600 pg/mL and you have no risk factors for deficiency, you can safely use semaglutide-only and monitor levels every 6 months. High baseline B12 (above 800 pg/mL) provides a buffer, and supplementation may be unnecessary for 12+ months.

Does semaglutide plus B12 cost more than semaglutide alone? Typically yes, by $20 to $50 per month depending on the compounding pharmacy. The cost difference reflects the added ingredient and formulation complexity. Weigh this against the cost of standalone B12 supplements ($10 to $15/month for sublingual) and the value of injection convenience.

Sources

1. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2022.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
3. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022.
4. Vidal-Alaball J et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 2005.
5. Ide H et al. The effect of high-dose methylcobalamin on diabetic neuropathy. J Neurol Sci. 2003.
6. Aasheim ET et al. Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr. 2008.
7. Dodge M et al. Effect of vitamin B12 supplementation on fatigue during caloric restriction: a randomized controlled trial. Nutr J. 2019.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022.
9. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
10. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022.
11. Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academies Press. 1998.
12. Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013.
13. Green R et al. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017.
14. Andrès E et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.